C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis

Cancer Causes and Control

Volumn 25, Issue 10, 2014, Pages 1397-1405

  Zhou, Bo ^a,b   Shu, Bin ^b   Yang, Jue ^a   Liu, Jing ^b   Xi, Tao ^a   Xing, Yingying ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

Colorectal cancer; CRP; IL 6; Meta analysis; Risk

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; IL6 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CANCER RISK; COLORECTAL CANCER; CYTOKINE PRODUCTION; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FOLLOW UP; HUMAN; MEDICAL LITERATURE; META ANALYSIS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; BLOOD; CASE CONTROL STUDY; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVAL; EARLY DIAGNOSIS; FEMALE; INCIDENCE; MALE; METABOLISM; RECTAL NEOPLASMS;

BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; INTERLEUKIN-6; MALE; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84911006198     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0445-8     Document Type: Article

References (57)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
4. Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816
5. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862
6. Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E et al (2011) Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg 15:576–583
7. Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645
8. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613
9. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A et al (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340–1350
10. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454
11. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP et al (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123:1133–1140
12. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15–26
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
14. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309
15. Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6:40–57
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51(264–269):W264
19. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW (2010) Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 39:699–709
20. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N et al (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case–control study. Am J Epidemiol 177:3–13
21. Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42:704–707
22. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010) C-reactive protein and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 102:202–206
23. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K et al (2013) Plasma C-reactive protein, genetic risk score, and risk of common cancers in the atherosclerosis risk in communities study. Cancer Causes Control 24:2077–2087
24. Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176:335–338
25. Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15:369–373
26. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226
27. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K et al (2005) Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639–1643
28. Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, Kemona-Chetnik I, Kemona H (2007) Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 120:585–590
29. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH et al (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97:1266–1270
30. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y et al (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98:540–544
31. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Kedra B, Lukaszewicz M et al (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423–1428
32. Kwon KA, Kim SH, Oh SY, Lee S, Han JY et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10:203
33. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU et al (2011) Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 104:51–59
34. Cooney RV, Chai W, Franke AA, Wilkens LR, Kolonel LN et al (2013) C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 22:1278–1288
35. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–590
36. Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M et al (2005) Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study. J Epidemiol 15(Suppl 2):S185–S189
37. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142:425–432
38. Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC et al (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14:2413–2418
39. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15:381–384
40. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC et al (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24:5216–5222
41. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S et al (2006) Plasma C-reactive protein and risk of colorectal cancer in a nested case–control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 15:690–695
42. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S et al (2006) A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66:2483–2487
43. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217–2224
44. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB et al (2010) Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case–control study within the European prospective investigation into cancer and nutrition. Am J Epidemiol 172:407–418
45. Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011) Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799–808
46. Lee S, Choe JW, Kim HK, Sung J (2011) High-sensitivity C-reactive protein and cancer. J Epidemiol 21:161–168
47. Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011) Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 20:297–307
48. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G et al (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 20:428–437
49. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M et al (2012) Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 72:3029–3037
50. Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y et al (2013) Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 132:2648–2658
51. Song M, Wu K, Ogino S, Fuchs CS, Giovannucci EL et al (2013) A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 108:1891–1898
52. Wu J, Cai Q, Li H, Cai H, Gao J et al (2013) Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis 34:2799–2803
53. Itzkowitz SH, Yio X (2004) Inflammation and cancer IV: colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17
54. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS et al (2004) Comparison of risk factors for colon and rectal cancer. Int J Cancer 108:433–442
55. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403–408
56. Zhou B, Liu J, Wang ZM, Xi T (2012) C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 7:e43075
57. Green J, Czanner G, Reeves G, Watson J, Wise L et al (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case–control study within a prospective cohort, and meta-analysis. Int J Cancer 130:2387–2396